newsfilter
← Latest News
GlobeNewswire·

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company